Dydrogesterone (Duphaston) - Comprehensive Research Paper

Document Version: 1.0 Last Updated: 2025-12-24 Classification: HRT Research - Female Progestins Paper Number: 35 of 76

1. Summary

1.1 Executive Summary

Dydrogesterone (Duphaston) is a synthetic retroprogesterone (stereoisomer of progesterone) used as the progestin component in hormone replacement therapy (HRT) for postmenopausal women. It is characterized by a 9β,10α stereochemistry (vs. natural progesterone's 9α,10β configuration), resulting in unique pharmacological properties including high oral bioavailability and selective progesterone receptor agonism.

Key Distinguishing Features:

• Retroprogesterone structure: First clinically used stereoisomer of natural progesterone
• Selective PR agonism: NO androgenic, estrogenic, glucocorticoid, or mineralocorticoid activity
• High oral bioavailability: 28% (vs. <10% for micronized progesterone)
• Metabolically stable: 4,6-diene-3-one structure resists hepatic degradation
• Proven endometrial protection: Effective at 10-20 mg/day doses

Clinical Efficacy (Combined with Estradiol):

• Vasomotor symptom relief: 70-80% reduction in hot flashes with E2 + dydrogesterone combinations
• Endometrial protection: 99.5% protection rate (only 1/187 women developed simple hyperplasia in 12-month study)
• Bone density preservation: +1.5-2.0% lumbar spine BMD at 24 months (comparable to other HRT regimens)

Safety Profile:

• Breast cancer risk: Lower than synthetic progestins (OR 1.32 for 5-9 years vs. OR 1.76-2.16 for MPA/norethindrone)
• VTE risk: Lowest among oral HRT combinations (comparable to micronized progesterone)
• Cardiovascular safety: Neutral effects when combined with transdermal estradiol
• No androgenic side effects: No acne, hirsutism, or weight gain

Current Availability:

• United States: NOT AVAILABLE - Withdrawn 1997 (commercial reasons, NOT safety/efficacy concerns)
• Europe (excluding UK): Available as Femoston (E2/dydrogesterone combination)
• Australia: Available
• United Kingdom: Discontinued 2008

Common Formulations:

| Product | Estradiol | Dydrogesterone | Regimen | Availability | |---

Goal Relevance:

• Reduce hot flashes and manage menopause symptoms effectively
• Protect bone health and maintain bone density during menopause
• Achieve hormone balance without unwanted side effects like weight gain or acne
• Find a safer hormone replacement therapy option with lower breast cancer risk
• Support endometrial health and prevent hyperplasia during hormone therapy
• Minimize the risk of blood clots while undergoing hormone replacement therapy
• Enhance overall quality of life during menopause with a reliable HRT option

------|-----------|----------------|---------|--------------| | Femoston-conti 0.5/2.5 | 0.5 mg | 2.5 mg | Continuous combined | Europe | | Femoston-conti 1/5 | 1 mg | 5 mg | Continuous combined | Europe | | Femoston 1/10 | 1 mg | 10 mg | Sequential (14 days) | Europe | | Femoston 2/10 | 2 mg | 10 mg | Sequential (14 days) | Europe | | Duphaston | None | 10 mg | Progestin-only | Europe, Asia |

1.2 Chemical and Pharmacological Classification

Chemical Name: 9β,10α-Pregna-4,6-diene-3,20-dione Molecular Formula: C₂₁H₂₈O₂ Molecular Weight: 312.45 g/mol CAS Number: 152-62-5

Classification:

• Drug Class: Progestin (synthetic progesterone analogue)
• Subclass: Retroprogesterone (pregnane derivative, progesterone stereoisomer)
• Generation: First-generation retroprogesterone
• Route: Oral (tablet)

Structural Characteristics:

Dydrogesterone differs from natural progesterone by two stereochemical inversions:

1. C10 methyl group: α-orientation (vs. β in progesterone)
2. C9 hydrogen: β-orientation (vs. α in progesterone)
3. Additional double bond: C6=C7 (4,6-diene structure vs. progesterone's 4-ene)

This 9β,10α configuration combined with the 4,6-diene-3-one structure confers:

• Metabolic stability: Resists 17α-hydroxylation and 5α-reduction (unlike progesterone)
• Oral activity: High bioavailability (28%) without first-pass hepatic inactivation
• Selective PR binding: No cross-reactivity with androgen, estrogen, glucocorticoid receptors

1.3 Historical Background

Development Timeline:

• 1950s: Dydrogesterone synthesized by Duphar Pharmaceuticals (Netherlands)
• 1961: FDA approval in United States (brand name: Gynorest)
• 1962: First marketed in Europe as Duphaston
• 1970s-1980s: Widely adopted for HRT in Europe, Asia
• 1997: Withdrawn from U.S. market (commercial reasons - indications no longer commercially viable)
• 2007: FDA determination that withdrawal was NOT due to safety/efficacy concerns
• 2010: Femoston-conti 0.5/2.5 approved in Europe (ultra-low dose combination)
• 2024: Remains widely used in Europe (excluding UK), Asia, Australia

Key Milestones:

1. First retroprogesterone for clinical use: Dydrogesterone was the first stereoisomer of progesterone developed for therapeutic use
2. Endometrial protection data (1990s): Large European studies established efficacy for preventing endometrial hyperplasia
3. Breast cancer safety data (2000s-2010s): French E3N cohort and Finnish registry studies showed lower breast cancer risk vs. synthetic progestins
4. VTE safety data (2007): ESTHER study demonstrated no increased VTE risk vs. transdermal E2 alone

1.4 Clinical Context and Rationale

Why Dydrogesterone Was Developed:

Natural progesterone has poor oral bioavailability (<10%) due to extensive first-pass hepatic metabolism. Early synthetic progestins (norethindrone, levonorgestrel, MPA) had good oral bioavailability but carried androgenic, estrogenic, or glucocorticoid side effects.

Dydrogesterone's Design Goals:

1. Maintain progesterone's selectivity: No androgenic/estrogenic/glucocorticoid effects
2. Improve oral bioavailability: Bypass first-pass metabolism
3. Provide robust endometrial protection: Match or exceed synthetic progestins' efficacy

Clinical Advantages Over Other Progestins:

Current Role in HRT:

• Europe (excluding UK): First-line progestin for HRT (alongside micronized progesterone)
• Asia: Widely used for HRT and threatened miscarriage
• United States: Not available (patients use micronized progesterone or MPA instead)

2. Mechanism of Action

2.1 Molecular Mechanism

Progesterone Receptor Agonism:

Dydrogesterone is a selective agonist of the progesterone receptor (PR), with binding affinity comparable to natural progesterone for both PR-A and PR-B isoforms.

Mechanism:

1. Receptor binding: Dydrogesterone binds to cytoplasmic PR (both PR-A and PR-B)
2. Receptor activation: Ligand-receptor complex translocates to nucleus
3. DNA binding: PR dimer binds to progesterone response elements (PREs) on target genes
4. Transcriptional regulation:
   • Upregulation: 17β-HSD type 2 (converts E2 → estrone, reducing local estrogen activity)
   • Downregulation: Estrogen receptor α (ER-α) expression
   • Upregulation: PTEN (tumor suppressor, inhibits PI3K/AKT pathway)

Endometrial Effects:

Dydrogesterone opposes estrogen-induced endometrial proliferation by:

1. Inhibiting ER-α expression: Reduces endometrial estrogen sensitivity
2. Converting E2 → E1: Upregulates 17β-HSD type 2 (inactivates estradiol locally)
3. Inducing secretory transformation: Promotes glycogen accumulation, glandular secretion
4. Promoting decidualization: Prepares endometrium for implantation (in pregnancy) or shedding (in HRT)

Key Distinction from Progesterone:

Unlike progesterone, dydrogesterone's 4,6-diene-3-one structure resists:

• 5α-reduction: Cannot convert to 5α-dihydroprogesterone (neurosteroid precursor)
• 3α-reduction: Cannot convert to allopregnanolone (GABA-A receptor agonist)

Clinical implication: Dydrogesterone does NOT have sedative/anxiolytic effects (unlike micronized progesterone, which produces allopregnanolone metabolites with CNS effects).

2.2 Receptor Selectivity Profile

Progesterone Receptor (PR):

• Binding affinity: Ki = 1.5 nM (comparable to progesterone Ki = 1.0 nM)
• PR-A vs. PR-B: Equal agonism of both isoforms
• Functional activity: Full agonist (100% efficacy vs. progesterone)

Androgen Receptor (AR):

• Binding affinity: <1% of progesterone (essentially no binding)
• Androgenic activity: None (no acne, hirsutism, voice deepening)
• Antiandrogenic activity: None (unlike cyproterone acetate, drospirenone)

Estrogen Receptor (ER):

• Binding affinity: <1% of progesterone
• Estrogenic activity: None
• Antiestrogenic activity: Indirect (via PR-mediated downregulation of ER-α in endometrium)

Glucocorticoid Receptor (GR):

• Binding affinity: <1% of progesterone
• Glucocorticoid activity: None (no HPA axis suppression, no hyperglycemia)
• Antiglucocorticoid activity: None

Mineralocorticoid Receptor (MR):

• Binding affinity: ~10% of progesterone (weak)
• Antimineralocorticoid activity: Weak (unlike drospirenone, which has potent antimineralocorticoid effects)
• Clinical relevance: No significant effect on blood pressure, potassium levels

Summary Table:

Clinical Significance:

Dydrogesterone's selective PR agonism translates to:

• No androgenic side effects: Unlike norethindrone, levonorgestrel (no acne, hirsutism, weight gain)
• No estrogenic side effects: Unlike some synthetic progestins with residual estrogenic activity
• No glucocorticoid effects: Unlike MPA (which has weak glucocorticoid activity → hyperglycemia risk)
• No significant antimineralocorticoid effects: Unlike drospirenone (no hyperkalemia risk)

2.3 Comparison to Natural Progesterone

Structural Differences:

Metabolic Differences:

Pharmacological Consequences:

1. Oral bioavailability:

   • Progesterone: <10% (extensive first-pass 17α-hydroxylation)
   • Dydrogesterone: 28% (resists first-pass metabolism)

2. CNS effects:

   • Progesterone: Sedative, anxiolytic (via allopregnanolone)
   • Dydrogesterone: No CNS effects (no allopregnanolone production)

3. Dosing:

   • Progesterone: 200-300 mg/day for endometrial protection
   • Dydrogesterone: 10-20 mg/day (10-15× lower dose)

Clinical Trade-offs:

3. Indications and Usage

3.1 FDA-Approved Indications (Historical - No Longer Available in U.S.)

Gynorest (dydrogesterone) was approved in 1961 for:

1. Menstrual disorders:

   • Amenorrhea (secondary)
   • Irregular menstruation
   • Functional uterine bleeding

2. Endometriosis

3. Dysmenorrhea

4. Threatened or habitual abortion (now obsolete indication)

Withdrawal from U.S. Market (1997):

• Reason: Commercial decision (indications no longer commercially viable, not safety/efficacy concerns)
• FDA determination (2007): Product was NOT withdrawn for reasons of safety or effectiveness
• Current status: ANDAs (generic applications) could be approved if submitted, but none have been

3.2 EMA-Approved Indications (Europe, Excluding UK)

Femoston (estradiol/dydrogesterone combination) approved for:

1. Hormone replacement therapy (HRT):
   • Treatment of vasomotor symptoms (hot flashes, night sweats) associated with menopause
   • Prevention of osteoporosis in postmenopausal women at high fracture risk

Duphaston (dydrogesterone alone) approved for:

1. Progestin-only indications:
   • Dysfunctional uterine bleeding
   • Secondary amenorrhea
   • Irregular cycles
   • Premenstrual syndrome (PMS)
   • Threatened or recurrent miscarriage (up to 20 weeks gestation)
   • Luteal phase support in assisted reproductive technology (ART)

3.3 Dosing Regimens in HRT

Sequential (Cyclic) HRT:

Indication: Women in early menopause (within 1 year of last menstrual period) who prefer regular withdrawal bleeds

Regimen:

• Days 1-14: Estradiol 1 mg or 2 mg daily (alone)
• Days 15-28: Estradiol 1 mg or 2 mg + dydrogesterone 10 mg daily
• Withdrawal bleed: Typically occurs Days 25-28 or Days 1-4 of next cycle

Alternative sequential regimen:

• Continuous estradiol: 2 mg daily throughout cycle
• Dydrogesterone: 10-20 mg daily for 14 days per 28-day cycle

Clinical notes:

• Higher dydrogesterone dose (20 mg) may be needed if:
  • Endometrial thickness >5 mm on ultrasound
  • Breakthrough bleeding persists
  • Patient has obesity (BMI >30, higher estrogen levels)

Continuous Combined HRT:

Indication: Women >1 year post-menopause who prefer amenorrhea (no withdrawal bleeds)

Standard dose:

• Femoston-conti 1/5: Estradiol 1 mg + dydrogesterone 5 mg daily (continuous)

Low dose:

• Femoston-conti 0.5/2.5: Estradiol 0.5 mg + dydrogesterone 2.5 mg daily (continuous)

Clinical notes:

• Initial irregular bleeding: Common in first 3-6 months (50-60% of women)
• Amenorrhea rate: 80-90% by Month 12
• If persistent bleeding after 6 months: Investigate with endometrial biopsy or transvaginal ultrasound

Progestin-Only (for Endometrial Protection with External Estrogen):

Indication: Women using transdermal estradiol patches/gels who need oral progestin

Regimen:

• Cyclic: Dydrogesterone 10-20 mg daily for 14 days per 28-day cycle
• Continuous: Dydrogesterone 5 mg daily (with continuous transdermal E2)

Example:

• Estradiol gel (Divigel) 1 mg/day applied to skin + dydrogesterone 10 mg PO daily (Days 15-28 of cycle)

3.4 Off-Label Uses in HRT

1. Transgender Hormone Therapy (Feminizing HRT):

Indication: Endometrial protection in transgender women using high-dose estrogen (who have retained uterus after orchiectomy)

Rationale:

• Transgender women on feminizing HRT with intact uterus require progestin to prevent endometrial hyperplasia
• Dydrogesterone offers progestin protection without androgenic effects (important for feminization goals)

Dosing:

• Cyclic: Dydrogesterone 10 mg daily for 14 days per month (if using cyclic estrogen)
• Continuous: Dydrogesterone 5 mg daily (if using continuous estrogen)

Clinical notes:

• Most transgender women undergo hysterectomy (if uterus present), eliminating need for progestin
• Progestin use in transgender women without uterus is controversial (some report breast development benefits, but data limited)

2. Premature Ovarian Insufficiency (POI):

Indication: HRT in women <40 years old with premature menopause

Rationale:

• POI patients require HRT until age ~50-52 (natural menopause age) for bone/cardiovascular protection
• Dydrogesterone's favorable safety profile (low VTE/breast cancer risk) ideal for long-duration HRT

Dosing:

• Sequential: E2 2 mg (Days 1-28) + dydrogesterone 10 mg (Days 15-28)
• Continuous (if amenorrhea preferred): E2 1 mg + dydrogesterone 5 mg daily

Clinical notes:

• Higher estradiol doses often needed vs. postmenopausal HRT (2 mg vs. 0.5-1 mg)
• Sequential regimens preferred in young POI patients to maintain regular cycles

3. PCOS (Polycystic Ovary Syndrome) - Cycle Regulation:

Indication: Endometrial protection and cycle regulation in PCOS patients not seeking pregnancy

Rationale:

• PCOS causes chronic anovulation → unopposed estrogen → endometrial hyperplasia risk
• Dydrogesterone induces secretory transformation and withdrawal bleeding

Dosing:

• Cyclic: Dydrogesterone 10 mg daily for 14 days per month (induces withdrawal bleed)
• Alternative: Dydrogesterone 20 mg daily for 12-14 days every 2-3 months (if less frequent bleeding preferred)

Clinical notes:

• Dydrogesterone does NOT improve metabolic features of PCOS (insulin resistance, hyperandrogenism)
• Metformin + dydrogesterone combination often used

4. Dosing and Administration

4.1 Available Formulations

Dydrogesterone-Only (Duphaston):

Combination Products (Estradiol/Dydrogesterone - Femoston):

4.2 Standard Dosing Regimens

For HRT (Postmenopausal Women with Intact Uterus):

Sequential/Cyclic Therapy:

Goal: Regular withdrawal bleeds, suitable for perimenopausal/early postmenopausal women

Regimen Options:

1. Femoston 1/10:

   • Days 1-14: 1 tablet white (E2 1 mg alone)
   • Days 15-28: 1 tablet grey (E2 1 mg + dydrogesterone 10 mg)
   • Withdrawal bleed typically Days 25-28 or Days 1-4 of next cycle

2. Femoston 2/10:

   • Days 1-14: 1 tablet red (E2 2 mg alone)
   • Days 15-28: 1 tablet yellow (E2 2 mg + dydrogesterone 10 mg)
   • Higher estradiol dose for severe symptoms

3. Custom regimen (if using separate estradiol product):

   • Estradiol (oral or transdermal): Continuous throughout cycle
   • Duphaston 10 mg: 1 tablet daily for Days 15-28 (14 days per cycle)

When to use sequential vs. continuous:

• Sequential preferred if:

  • <1 year post-menopause (tolerance for monthly bleeds)
  • Patient prefers regular cycles (psychological reassurance of "normal periods")
  • Breast tenderness with continuous combined therapy

• Continuous preferred if:

  • 1 year post-menopause (endometrium atrophic, lower bleeding risk)

  • Patient prefers amenorrhea (no tolerance for monthly bleeds)
  • Irregular bleeding with sequential therapy

Continuous Combined Therapy:

Goal: Amenorrhea (no withdrawal bleeds), suitable for >1 year post-menopause

Regimen Options:

1. Femoston-conti 1/5:

   • 1 tablet daily (E2 1 mg + dydrogesterone 5 mg)
   • Standard dose for most postmenopausal women

2. Femoston-conti 0.5/2.5:

   • 1 tablet daily (E2 0.5 mg + dydrogesterone 2.5 mg)
   • Ultra-low dose for women with mild symptoms or long-term use

Breakthrough Bleeding Management:

• Months 1-3: Irregular bleeding/spotting in 50-60% of women (normal, no intervention needed)
• Months 4-6: Bleeding decreases (30-40% of women)
• After Month 6: Amenorrhea in 80-90% of women

If bleeding persists after 6 months:

1. Rule out pathology: Endometrial biopsy or transvaginal ultrasound (exclude hyperplasia, polyps, cancer)
2. Increase progestin dose: Switch from 2.5 mg → 5 mg dydrogesterone (or add extra 5 mg for 10 days/month)
3. Consider sequential regimen: If continuous combined not tolerated

Progestin-Only (with External Estrogen Source):

Goal: Endometrial protection in women using non-oral estrogen (patches, gels)

Cyclic Regimen:

• Duphaston 10 mg: 1 tablet daily for 14 days per 28-day cycle (Days 15-28)
• Higher dose (20 mg): 2 tablets daily for 14 days if endometrial thickness >5 mm or obesity (BMI >30)

Continuous Regimen:

• Duphaston 5 mg: Half tablet daily (continuous) with continuous transdermal estradiol
• Note: 5 mg tablets not available; some patients split 10 mg tablets or take 10 mg every other day

Example:

• Estradiol gel (Divigel) 1 mg/day (applied to thigh) + Duphaston 10 mg PO (Days 15-28 each month)

4.3 Dose Adjustments

For Symptom Control:

If vasomotor symptoms NOT controlled on standard dose:

1. Increase estradiol dose FIRST (dydrogesterone dose unchanged):

   • Femoston 1/10 → Femoston 2/10 (sequential)
   • Femoston-conti 0.5/2.5 → Femoston-conti 1/5 (continuous)

2. Do NOT increase dydrogesterone unless endometrial protection inadequate (dydrogesterone does not treat hot flashes)

For Endometrial Protection:

If endometrial thickness >5 mm on ultrasound despite progestin use:

1. Increase dydrogesterone dose:

   • Sequential: 10 mg → 20 mg daily (for 14 days)
   • Continuous: 2.5 mg → 5 mg daily OR 5 mg → 10 mg daily

2. Extend progestin duration (sequential regimen):

   • 14 days → 21 days per cycle (e.g., Days 8-28 instead of Days 15-28)

3. Switch to continuous combined if sequential regimen inadequate

For Obesity (BMI >30):

Rationale: Adipose tissue aromatizes androgens → estrone, increasing total estrogen exposure

Dose adjustment:

• Increase dydrogesterone dose: 10 mg → 20 mg (sequential) or 5 mg → 10 mg (continuous)
• Monitor endometrial thickness: Annual transvaginal ultrasound recommended

4.4 Administration Instructions

Timing:

• Cyclic regimen: Take at same time each day; start Day 1 (first day of calendar month or first day of cycle)
• Continuous combined: Take at same time each day (no breaks between packs)

With or Without Food:

• Can be taken with or without food
• Taking with food may reduce nausea (if occurs)

Missed Dose:

• If <12 hours late: Take missed dose immediately, continue regular schedule
• If >12 hours late: Skip missed dose, take next dose at regular time (do NOT double dose)
• Sequential regimen: If multiple doses missed during progestin phase (Days 15-28), may cause irregular bleeding

Storage:

• Room temperature: Store at 20-25°C (68-77°F)
• Protect from moisture: Keep in original blister pack until use
• Expiration: Check expiration date; do not use expired tablets

Disposal:

• Do NOT flush: Dispose in household trash (in sealed container)
• Medication take-back programs: Preferred disposal method (prevents environmental contamination)

4.5 Special Dosing Considerations

Perimenopausal Women (Still Having Irregular Periods):

Challenge: Difficult to time progestin phase if cycles unpredictable

Approach:

1. Calendar-based cyclic regimen: Start progestin on Day 15 of each calendar month (regardless of bleeding)
2. OR continuous combined regimen: Easier for irregular cycles (no need to time progestin)

Clinical note: Breakthrough bleeding common in perimenopause (overlapping endogenous hormones + HRT)

Women with History of Endometriosis:

Rationale: Endometriosis may persist/recur with unopposed estrogen

Dose adjustment:

• Higher progestin dose: Dydrogesterone 20 mg daily (continuous) to suppress endometriotic lesions
• OR continuous combined regimen: Prevents cyclical estrogen stimulation of endometriotic tissue

Clinical note: Some clinicians use dydrogesterone-only (no estrogen) for endometriosis treatment

Women with Previous Endometrial Hyperplasia:

Rationale: Higher risk of recurrence; requires robust endometrial protection

Dose adjustment:

• Increase progestin dose: Dydrogesterone 20 mg daily (continuous combined)
• OR longer progestin exposure: 21 days per cycle (instead of 14 days)
• Monitoring: Endometrial biopsy at 6-12 months to confirm resolution

Alternative: Some clinicians avoid HRT entirely in this population; use non-hormonal alternatives (fezolinetant, SSRIs)

5. Pharmacokinetics

5.1 Absorption

Oral Bioavailability:

• 28% (vs. <10% for micronized progesterone)
• High bioavailability due to metabolic stability (4,6-diene structure resists first-pass 17α-hydroxylation)

Tmax (Time to Peak Concentration):

• Dydrogesterone: 0.5-2.5 hours (median 1 hour)
• 20α-DHD metabolite: 1.5-3.0 hours

Food Effects:

• No clinically significant effect on absorption
• AUC and Cmax similar with/without food
• Recommendation: Can be taken with or without food

Dose Linearity:

• Linear pharmacokinetics in dose range 2.5-20 mg
• Doubling dose → doubling AUC and Cmax

Steady-State:

• Achieved after 2-3 days of daily dosing
• No accumulation with repeated dosing (half-life <24 hours)

5.2 Distribution

Volume of Distribution (Vd):

• Not extensively published (estimated ~30-50 L)

Protein Binding:

• Dydrogesterone: >90% bound to plasma proteins
  • Albumin: Primary binding protein (~85%)
  • SHBG: Minimal binding (<5%, unlike testosterone which binds 60% to SHBG)
  • CBG (corticosteroid-binding globulin): No binding
• 20α-DHD metabolite: >90% bound (similar to parent drug)

Tissue Distribution:

• Endometrium: High concentration (target tissue)
• Breast: Moderate concentration
• CNS: Minimal penetration (does not cross blood-brain barrier efficiently due to lack of allopregnanolone metabolites)

Clinical implication: Dydrogesterone has NO sedative effects (unlike progesterone, which produces CNS-active allopregnanolone)

5.3 Metabolism

Primary Metabolic Pathway:

20α-reduction: Dydrogesterone → 20α-dihydrodydrogesterone (20α-DHD)

• Enzyme: 20α-HSD (20α-hydroxysteroid dehydrogenase, AKR1C1)
• Location: Liver, endometrium
• Product: 20α-DHD (major circulating metabolite, ~90% of excreted material)

Key Metabolic Stability:

Dydrogesterone resists the following pathways (unlike progesterone):

1. 5α-reduction: NO conversion to 5α-dihydroprogesterone (4,6-diene structure prevents)
2. 17α-hydroxylation: NO conversion to 17-hydroxyprogesterone (9β,10α config resists CYP17A1)
3. 3α-reduction: NO conversion to allopregnanolone (no 5α-DHP precursor)

Metabolic Profile Comparison:

Clinical Significance:

• No neurosteroid metabolites: Dydrogesterone does NOT produce allopregnanolone (no sedation, no GABA-A effects)
• No androgenic metabolites: No conversion to androgens (vs. progesterone → androstenedione pathway)
• Metabolically stable: Resists extensive first-pass metabolism (explains high oral bioavailability)

5.4 Excretion

Route of Excretion:

• Urine: ~90% (primarily as 20α-DHD conjugates)
• Feces: ~10% (biliary excretion)

Half-Life:

Clearance:

• Renal clearance: Primarily via glomerular filtration (as conjugated metabolites)
• No dose adjustment needed in mild-moderate renal impairment (no data for severe renal impairment)

Time to Steady-State:

• 2-3 days of once-daily dosing
• Based on 20α-DHD half-life (14-17 hours)

Washout Period:

• 5-7 days after discontinuation for complete elimination

5.5 Pharmacokinetic Parameters (Summary Table)

Single Dose (Dydrogesterone 10 mg):

Steady-State (Dydrogesterone 10 mg daily):

6. Side Effects and Adverse Reactions

6.1 Common Side Effects (≥1%)

Menstrual/Uterine Effects:

Breast Effects:

Gastrointestinal:

Neurological:

Dermatological:

Important Note:

Dydrogesterone does NOT cause:

• Sedation/drowsiness: Unlike micronized progesterone (no allopregnanolone production)
• Androgenic effects: No acne, hirsutism, voice deepening, male-pattern baldness
• Weight gain: No significant weight change in clinical trials (unlike MPA, norethindrone)
• Mood changes: No depression, anxiety (unlike some synthetic progestins)

6.2 Serious Adverse Reactions (<1%)

Thromboembolic Events:

Venous Thromboembolism (VTE):

• Incidence: 0.1-0.3% per year with dydrogesterone + transdermal estradiol (LOWEST among oral HRT combinations)
• Risk factors: Age >60, obesity, smoking, prior VTE, thrombophilia, prolonged immobility
• Clinical presentation: Deep vein thrombosis (DVT) - leg swelling, pain, warmth; Pulmonary embolism (PE) - chest pain, dyspnea, hemoptysis

Arterial Thromboembolism:

• Stroke: 0.1-0.2% per year (comparable to non-HRT users with transdermal E2)
• Myocardial infarction: 0.05-0.1% per year (rare)

Management:

• Screen for VTE risk factors before initiating HRT
• Prefer transdermal estradiol over oral in women with VTE risk factors (dydrogesterone safe with either route)
• Discontinue HRT immediately if VTE/stroke occurs
• Restart HRT: Generally NOT recommended after VTE/stroke event

Breast Cancer:

Risk with Dydrogesterone vs. Other Progestins:

Key Findings:

• Dydrogesterone has LOWER breast cancer risk than MPA and norethindrone
• Similar risk to micronized progesterone with long-term use (>5 years)
• Absolute risk increase: ~1-2 extra breast cancer cases per 1,000 women per year (with 5+ years use)

Screening Recommendations:

• Mammography: Every 1-2 years (same as non-HRT users)
• Clinical breast exam: Annual (by physician)
• Self-breast exam: Monthly (optional, patient preference)

Endometrial Hyperplasia/Cancer:

Risk with Adequate Progestin Protection:

• Endometrial hyperplasia: 0.5-1% per year (vs. 10-20% with unopposed estrogen)
• Endometrial cancer: <0.1% per year (comparable to non-HRT users)

Critical: Dydrogesterone provides excellent endometrial protection when dosed appropriately (10-20 mg cyclic or 5 mg continuous)

Warning Signs:

• Irregular bleeding after 6 months of continuous combined HRT
• Heavy bleeding or bleeding after menopause (if not on HRT)
• Endometrial thickness >5 mm on transvaginal ultrasound

Management:

• Endometrial biopsy if irregular bleeding persists >6 months
• Increase dydrogesterone dose if hyperplasia detected (e.g., 10 mg → 20 mg)
• Consider discontinuing HRT if atypical hyperplasia or cancer diagnosed

6.3 Bleeding Patterns (Expected vs. Abnormal)

Sequential/Cyclic HRT (Femoston 1/10, Femoston 2/10):

Expected Bleeding Pattern:

• Withdrawal bleed: Days 25-28 of cycle (or Days 1-4 of next cycle)
• Duration: 3-5 days
• Flow: Light to moderate (similar to natural menstrual period)
• Timing: Predictable (occurs within 2-3 days after stopping progestin)

Abnormal Bleeding Patterns (Require Investigation):

1. Heavy bleeding (>7 days or soaking pads/tampons): Rule out endometrial hyperplasia, polyps
2. Bleeding during estrogen-only phase (Days 1-14): Suggests inadequate progestin protection or pathology
3. No withdrawal bleed for >3 consecutive cycles: May indicate endometrial atrophy (benign) or pregnancy (if premenopausal)

Continuous Combined HRT (Femoston-conti 0.5/2.5, 1/5):

Expected Bleeding Pattern:

Abnormal Bleeding Patterns (Require Investigation):

1. Heavy bleeding at any time: Endometrial biopsy to rule out hyperplasia/cancer
2. Persistent bleeding after 12 months: Transvaginal ultrasound to assess endometrial thickness
3. Bleeding after amenorrhea established: Suggests pathology (polyp, hyperplasia, cancer)

Investigation Protocol for Abnormal Bleeding:

1. Transvaginal ultrasound: Measure endometrial thickness

   • <5 mm: Reassure (endometrial atrophy, benign)
   • 5-10 mm: Consider increasing dydrogesterone dose

   • 10 mm: Endometrial biopsy REQUIRED (rule out hyperplasia/cancer)

2. Endometrial biopsy: If ultrasound shows >10 mm thickness or persistent bleeding

3. Hysteroscopy: If biopsy inconclusive or polyps suspected

6.4 Cardiovascular Safety

Stroke Risk:

Data from Observational Studies:

• Transdermal E2 + dydrogesterone: NO increased stroke risk (HR 1.0, 95% CI 0.8-1.3) vs. non-users
• Oral E2 + dydrogesterone: Slightly increased risk (HR 1.3, 95% CI 1.0-1.7)
• Oral E2 + MPA: Increased risk (HR 1.8, 95% CI 1.4-2.3)

Clinical Implication:

• Prefer transdermal estradiol over oral estradiol (lower stroke risk)
• Dydrogesterone is safest progestin for stroke risk (no adverse effects on coagulation)

Myocardial Infarction (MI) Risk:

WHI and Observational Data:

• Dydrogesterone + E2: NO increased MI risk in healthy women aged <60 or within 10 years of menopause
• Timing hypothesis: Early initiation (<10 years post-menopause) may be cardioprotective; late initiation (>10 years) increases risk

Key Factors Affecting MI Risk:

Recommendation:

• Initiate HRT within 10 years of menopause in women without CVD risk factors
• Use transdermal estradiol + dydrogesterone for optimal cardiovascular safety

Hypertension:

Data from French E3N Cohort:

• Dydrogesterone + E2: NO increased risk of incident hypertension (OR 1.0, 95% CI 0.8-1.2)
• Pregnane derivatives (MPA, nomegestrol): Increased risk (OR 1.4-1.6)
• Norpregane derivatives (norethindrone, levonorgestrel): Increased risk (OR 1.3-1.5)

Clinical Implication:

• Dydrogesterone does NOT raise blood pressure (unlike MPA, norethindrone)
• Safe for women with controlled hypertension (if blood pressure <140/90 mmHg)

Lipid Effects:

Effects of Dydrogesterone + Oral Estradiol on Lipid Profile:

Key Finding:

• Dydrogesterone does NOT negate estrogen's beneficial HDL increase (unlike androgenic progestins like norethindrone)
• Neutral effect on triglycerides (does not worsen estrogen-induced hypertriglyceridemia)

Clinical Implication:

• Safe for women with dyslipidemia (LDL >130 mg/dL)
• Caution if triglycerides >400 mg/dL (estrogen-induced hypertriglyceridemia may worsen pancreatitis risk)

6.5 Metabolic Effects

Glucose and Insulin:

Effects of Dydrogesterone + Estradiol on Glucose Metabolism:

Clinical Implication:

• Dydrogesterone does NOT cause insulin resistance (unlike MPA, which has weak glucocorticoid activity)
• Safe for women with type 2 diabetes (if well-controlled, HbA1c <7.5%)

Body Weight and Body Composition:

Clinical Trial Data:

• No significant weight gain vs. placebo in 12-month trials
• Mean weight change: +0.5 kg (not statistically significant)
• Body composition: Slight decrease in visceral fat (estrogen effect); dydrogesterone neutral

Comparison to Other Progestins:

Clinical Implication:

• Dydrogesterone does NOT cause weight gain (unlike MPA, norethindrone)
• Patient counseling: Weight gain often attributed to HRT is usually due to aging/lifestyle, not HRT itself

6.6 Mood and Quality of Life

Mood Effects:

Clinical Trial Data:

• No adverse effects on mood in placebo-controlled trials
• Depression/anxiety scores: No difference vs. baseline or placebo
• Sleep quality: Improvement (likely due to reduced hot flashes, not direct dydrogesterone effect)

Comparison to Micronized Progesterone:

Clinical Implication:

• Dydrogesterone preferred if: Patient wants NO sedative effects, takes HRT in morning, or experiences drowsiness with progesterone
• Micronized progesterone preferred if: Patient has insomnia or anxiety (allopregnanolone helps sleep/anxiety)

Quality of Life (MENQOL Scores):

Improvement from Baseline (E2 + Dydrogesterone vs. Placebo):

Clinical Implication:

• Significant QOL improvement with E2 + dydrogesterone vs. placebo
• Greatest benefit: Vasomotor symptoms (hot flashes)

7. Drug Interactions

7.1 CYP450 Enzyme Interactions

Dydrogesterone Metabolism:

• Primary enzyme: 20α-HSD (AKR1C1) - NOT a CYP450 enzyme
• Minor pathways: CYP3A4 (contributes <10% to metabolism)

Clinical Implication:

• Fewer drug interactions than progesterone (which is extensively metabolized by CYP3A4)
• CYP3A4 inducers/inhibitors have MINIMAL effect on dydrogesterone levels

CYP3A4 Inducers (May Slightly Decrease Dydrogesterone Levels):

Clinical Note:

• Impact is LESS than with progesterone or other progestins (because dydrogesterone is not primarily metabolized by CYP3A4)
• Irregular bleeding may signal reduced dydrogesterone levels (increase dose or switch to alternative progestin)

CYP3A4 Inhibitors (May Slightly Increase Dydrogesterone Levels):

Clinical Note:

• Increased dydrogesterone levels rarely cause toxicity (wide therapeutic window)
• Potential increased side effects: Breast tenderness, nausea (usually mild)

7.2 Hormonal Interactions

Thyroid Hormone (Levothyroxine):

Mechanism:

• Estrogen increases TBG (thyroxine-binding globulin) → binds more T4 → lower free T4
• Dydrogesterone has NO effect on TBG

Clinical Implication:

• Monitor TSH in women on levothyroxine when starting HRT (estrogen component may necessitate levothyroxine dose increase)
• Typical increase: 12.5-25 mcg/day levothyroxine

Management:

• Check TSH at baseline, then 6-8 weeks after starting HRT
• Adjust levothyroxine dose to maintain TSH 0.5-2.5 mIU/L

Corticosteroids:

Mechanism:

• Estrogen increases CBG (corticosteroid-binding globulin) → binds more cortisol → lower free cortisol
• Dydrogesterone has NO effect on CBG (no glucocorticoid activity)

Clinical Implication:

• No interaction between dydrogesterone and corticosteroids (prednisone, hydrocortisone)
• Monitor cortisol levels in women on chronic steroid replacement (estrogen may require dose adjustment)

Insulin and Oral Hypoglycemics:

Mechanism:

• Estrogen improves insulin sensitivity (beneficial)
• Dydrogesterone has NO effect on glucose/insulin (neutral)

Clinical Implication:

• HRT may IMPROVE glycemic control in women with type 2 diabetes
• Monitor glucose closely in first 3 months (may need to REDUCE insulin/metformin dose)

7.3 Anticoagulant Interactions

Warfarin:

Mechanism:

• Estrogen increases coagulation factors (II, VII, IX, X) → may slightly increase clotting risk
• Dydrogesterone has NO effect on coagulation

Clinical Implication:

• Monitor INR closely when starting HRT in women on warfarin
• Typical effect: INR may DECREASE slightly (estrogen pro-thrombotic) → may need to increase warfarin dose

Management:

• Check INR at baseline, Week 2, Week 4, Week 8 after starting HRT
• Adjust warfarin dose to maintain target INR (2.0-3.0 for most indications)

Direct Oral Anticoagulants (DOACs):

Clinical Note:

• DOACs do NOT require monitoring (unlike warfarin)
• Estrogen component may slightly increase VTE risk; monitor for signs of thrombosis

7.4 Other Drug Interactions

Tamoxifen (Breast Cancer Treatment):

Mechanism:

• Tamoxifen is a SERM (partial ER agonist/antagonist)
• Estrogen-containing HRT may antagonize tamoxifen's anti-estrogenic effects in breast tissue

Clinical Implication:

• HRT is CONTRAINDICATED in women on tamoxifen for breast cancer
• Alternative: Non-hormonal treatments for hot flashes (fezolinetant, SSRIs, gabapentin)

Raloxifene (Osteoporosis Treatment):

Mechanism:

• Raloxifene is a SERM with ER agonist effects on bone, ER antagonist effects on breast/uterus
• Combining with HRT is redundant (both provide bone protection)

Clinical Implication:

• Do NOT combine HRT with raloxifene (no additional benefit, increased VTE risk)
• Choose ONE: HRT (if symptomatic) OR raloxifene (if asymptomatic, focused on bone/breast cancer prevention)

8. Contraindications

8.1 Absolute Contraindications

The following conditions are ABSOLUTE contraindications to dydrogesterone-containing HRT:

1. Known or Suspected Breast Cancer:

• Current breast cancer: HRT may stimulate tumor growth
• History of breast cancer: Risk of recurrence (unless estrogen-receptor negative and oncologist approves)

Alternative: Non-hormonal treatments (fezolinetant, paroxetine, gabapentin)

2. Known or Suspected Estrogen-Dependent Neoplasia:

• Endometrial cancer (current or recent)
• Ovarian cancer (current or recent, especially estrogen-receptor positive)

Alternative: Non-hormonal HRT alternatives

3. Undiagnosed Abnormal Genital Bleeding:

• Rationale: Must rule out endometrial cancer, hyperplasia, polyps before starting HRT
• Workup required: Endometrial biopsy or transvaginal ultrasound

Management: Complete diagnostic workup BEFORE initiating HRT

4. Active or Recent (Within 1 Year) Venous Thromboembolism (VTE):

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)

Rationale: Estrogen increases VTE risk 2-3 fold (even with dydrogesterone's low-risk profile)

Alternative: Non-hormonal treatments

5. Active or Recent (Within 1 Year) Arterial Thromboembolic Disease:

• Myocardial infarction (MI)
• Stroke
• Transient ischemic attack (TIA)

Rationale: Estrogen may increase stroke risk in women with prior events

Alternative: Non-hormonal treatments

6. Known Thrombophilic Disorders:

• Factor V Leiden (homozygous or heterozygous with prior VTE)
• Prothrombin G20210A mutation
• Antithrombin deficiency
• Protein C or Protein S deficiency
• Antiphospholipid syndrome

Rationale: HRT dramatically increases VTE risk in these populations (up to 10-20 fold)

Alternative: Non-hormonal treatments; transdermal estradiol (if benefits outweigh risks in heterozygous Factor V Leiden without prior VTE)

7. Active Liver Disease:

• Acute hepatitis
• Decompensated cirrhosis
• Liver tumors (benign or malignant)

Rationale: Impaired estrogen metabolism → increased adverse effects

Alternative: Wait until liver function normalizes

8. Pregnancy:

• Known or suspected pregnancy

Rationale: Dydrogesterone (progestin) is NOT effective contraception; estrogen may harm fetus

Management: Pregnancy test before initiating HRT in women with any chance of pregnancy

9. Known Hypersensitivity:

• Allergy to dydrogesterone, estradiol, or any excipients

Clinical presentation: Rash, angioedema, anaphylaxis

Alternative: Alternative progestin (e.g., micronized progesterone)

8.2 Relative Contraindications (Require Caution)

The following conditions require CAREFUL RISK-BENEFIT ASSESSMENT:

1. Controlled Hypertension:

• Blood pressure <140/90 mmHg on medication: HRT generally safe (monitor BP every 3-6 months)
• Blood pressure >140/90 mmHg: Optimize BP control BEFORE starting HRT

Recommendation: Prefer transdermal estradiol + dydrogesterone (neutral effect on BP)

2. Diabetes Mellitus (Type 1 or Type 2):

• Well-controlled (HbA1c <7.5%): HRT generally safe
• Poorly controlled (HbA1c >8.0%): Optimize glycemic control BEFORE starting HRT

Recommendation: Monitor glucose closely in first 3 months (HRT may improve insulin sensitivity)

3. Migraine with Aura:

• Rationale: Estrogen may increase stroke risk in women with migraine with aura
• Risk: 2-3 fold increased stroke risk vs. migraine without aura

Management:

• Prefer transdermal estradiol (lower stroke risk vs. oral)
• Use lowest effective dose
• Monitor migraine frequency (if migraines worsen, discontinue HRT)

4. History of VTE >1 Year Ago (Resolved):

• Rationale: Prior VTE increases recurrence risk (~10-20% lifetime risk)
• Risk with HRT: 2-3 fold increased recurrence risk

Management:

• Thrombophilia screening (Factor V Leiden, prothrombin mutation, etc.)
• If no thrombophilia AND strong indication for HRT:
  • Use transdermal estradiol (lower VTE risk vs. oral)
  • Consider prophylactic anticoagulation (discuss with hematologist)

5. Gallbladder Disease:

• Rationale: Estrogen increases bile cholesterol saturation → gallstone formation
• Risk: 2-fold increased risk of cholecystitis in HRT users

Management:

• Prefer transdermal estradiol (avoids first-pass hepatic effects)
• Monitor for gallbladder symptoms (right upper quadrant pain, nausea after fatty meals)

6. Uterine Fibroids:

• Rationale: Estrogen may stimulate fibroid growth
• Risk: Variable (most fibroids stable or regress on HRT; some enlarge)

Management:

• Baseline pelvic ultrasound to document fibroid size
• Monitor symptoms (heavy bleeding, pelvic pressure)
• Discontinue HRT if fibroids significantly enlarge or cause symptoms

7. Endometriosis (History):

• Rationale: Estrogen may reactivate endometriotic lesions (even after hysterectomy)
• Risk: Variable (depends on residual endometriotic tissue)

Management:

• Use continuous combined HRT (dydrogesterone 5-10 mg daily prevents cyclical estrogen stimulation)
• Higher progestin dose: Dydrogesterone 10-20 mg daily (suppress endometriotic tissue)

8. Systemic Lupus Erythematosus (SLE):

• Rationale: Estrogen may exacerbate SLE (controversial data)
• Risk: Variable (some studies show no increased flare risk)

Management:

• Consult rheumatologist before initiating HRT
• Prefer transdermal estradiol
• Monitor disease activity (anti-dsDNA, complement levels)

9. Special Populations

9.1 Pregnancy and Lactation

Pregnancy Category:

• Not classified (dydrogesterone not used for contraception; HRT not indicated in reproductive-age women seeking pregnancy)

Use in Pregnancy (for Threatened Miscarriage):

• Indication: Dydrogesterone historically used for threatened or habitual abortion (up to 20 weeks gestation)
• Dose: 40 mg loading dose, then 10 mg every 8 hours until symptoms resolve, then taper
• Efficacy: Controversial (some studies show benefit, others show no effect vs. placebo)
• Safety: No increased risk of birth defects in large observational studies

Current Recommendations (2024):

• Progesterone (vaginal or IM) preferred over dydrogesterone for threatened miscarriage (stronger evidence base)
• Dydrogesterone still used in some countries (Europe, Asia) where vaginal progesterone unavailable

Lactation:

• Unknown if dydrogesterone excreted in breast milk
• Recommendation: Avoid HRT during breastfeeding (estrogen suppresses milk production)

9.2 Pediatric Use

Not indicated in children.

Exception: Adolescent girls with premature ovarian insufficiency (POI) may require HRT for:

• Pubertal induction
• Bone health
• Prevention of menopausal symptoms

Dosing (if indicated):

• Start with low-dose estrogen (e.g., estradiol 0.5 mg/day)
• Add dydrogesterone once breakthrough bleeding occurs (indicates endometrial stimulation)
• Cyclic regimen preferred in adolescents (maintains regular cycles)

9.3 Geriatric Use (Women >65 Years Old)

Initiation After Age 60 or >10 Years Post-Menopause:

Risks:

• Increased VTE risk: 2-3 fold (vs. 1.5-2 fold if started <60 years)
• Increased stroke risk: 1.5-2.0 fold (vs. neutral if started <60 years)
• Increased dementia risk: WHI Memory Study showed HR 2.05 for dementia with E2+MPA started >65 years (data for dydrogesterone lacking, but likely similar)

Recommendations:

• Do NOT initiate HRT in women >60 years or >10 years post-menopause (unless compelling indication)
• If already on HRT: Can continue if well-tolerated and benefits outweigh risks
• Discontinuation strategy: Consider tapering off HRT after age 60-65 (reassess annually)

Women Already on HRT at Age 65:

Continuation vs. Discontinuation:

• If started <60 years and still benefiting: Can continue (no arbitrary age limit)
• If mild symptoms: Consider tapering (reduce estradiol dose gradually over 6-12 months)
• If severe symptoms recur: Can resume HRT (weigh benefits vs. risks)

Annual Reassessment:

• Review indication (vasomotor symptoms? Bone health?)
• Assess risks (breast cancer, VTE, stroke risk factors)
• Patient preference (does patient want to continue?)

9.4 Renal Impairment

Mild-Moderate Renal Impairment (CrCl 30-89 mL/min):

• No dose adjustment needed
• Dydrogesterone metabolites excreted in urine, but accumulation not clinically significant

Severe Renal Impairment (CrCl <30 mL/min):

• Limited data
• Use with caution (monitor for increased side effects)

Hemodialysis:

• Unknown if dydrogesterone removed by hemodialysis
• Use with caution

9.5 Hepatic Impairment

Mild Hepatic Impairment (Child-Pugh A):

• Use with caution
• Monitor liver enzymes at baseline and every 6 months

Moderate-Severe Hepatic Impairment (Child-Pugh B or C):

• CONTRAINDICATED
• Rationale: Impaired estrogen metabolism → increased risk of adverse effects (VTE, hepatic dysfunction)

Cholestatic Liver Disease:

• Contraindicated (estrogen may worsen cholestasis)

History of Cholestatic Jaundice of Pregnancy or Pruritus of Pregnancy:

• Relative contraindication (HRT may precipitate recurrence)
• Monitor closely if HRT initiated

9.6 Transgender Hormone Therapy (Feminizing HRT)

Role of Dydrogesterone in Transgender Women:

Indication (if intact uterus after orchiectomy):

• Endometrial protection in transgender women using estrogen who have retained uterus

Dosing:

• Cyclic: Dydrogesterone 10 mg daily for 14 days per month (if using cyclic estrogen)
• Continuous: Dydrogesterone 5 mg daily (if using continuous estrogen)

Clinical Note:

• Most transgender women undergo hysterectomy (if uterus present), eliminating need for progestin
• Progestin use in transgender women WITHOUT uterus is controversial:
  • Some report breast development benefits (anecdotal)
  • No robust clinical trial data supporting this use
  • Potential downsides: Mood effects, weight gain (variable)

Current Recommendations (WPATH Guidelines):

• Progestin only if uterus present (for endometrial protection)
• NOT routinely recommended in transgender women without uterus

10. Monitoring Requirements

10.1 Baseline Evaluation (Before Initiating HRT)

Clinical History:

• Menopause status: Last menstrual period, menopausal symptoms
• Medical history: VTE, stroke, MI, breast cancer, endometrial cancer, liver disease
• Family history: Breast cancer, ovarian cancer, VTE, stroke
• Medication history: Current medications (check for drug interactions)
• Smoking status: Current or former smoker (increases VTE/stroke risk)

Physical Examination:

Laboratory Tests:

Imaging:

10.2 Ongoing Monitoring Schedule

Months 1-3 (Initial Titration Period):

Months 6-12:

10.3 Annual Reassessment

Clinical History:

• Symptom control: Are vasomotor symptoms controlled?
• Bleeding pattern: Any irregular bleeding? (requires investigation)
• Side effects: Breast tenderness, headaches, nausea?
• New medical conditions: VTE, stroke, MI, breast cancer diagnosis?
• Medication changes: New drugs with potential interactions?

Physical Examination:

Laboratory Tests (Annually or as Indicated):

Imaging:

10.4 Management of Breakthrough Bleeding

Bleeding on Continuous Combined HRT (Femoston-conti):

Months 1-6:

• Irregular spotting/bleeding: NORMAL (50-60% of women experience this)
• Management: Reassure; usually resolves by Month 6
• No investigation needed unless heavy bleeding (soaking pads/tampons)

After Month 6:

• Any bleeding after amenorrhea established: REQUIRES INVESTIGATION

Investigation Protocol:

1. Transvaginal ultrasound: Measure endometrial thickness

   • <5 mm: Reassure (endometrial atrophy, benign)
   • 5-10 mm: Increase dydrogesterone dose (e.g., 2.5 mg → 5 mg)

   • 10 mm: Endometrial biopsy REQUIRED

2. Endometrial biopsy: If ultrasound shows >10 mm thickness

   • Normal result (secretory/atrophic endometrium): Reassure
   • Hyperplasia (simple or complex): Increase dydrogesterone dose (or switch to cyclic regimen)
   • Atypical hyperplasia/cancer: Discontinue HRT immediately; refer to gynecologic oncology

Bleeding on Sequential/Cyclic HRT (Femoston 1/10, 2/10):

Expected Pattern:

• Withdrawal bleed: Days 25-28 of cycle (during or after progestin phase)
• Duration: 3-5 days
• Flow: Light to moderate

Abnormal Patterns Requiring Investigation:

1. Bleeding during estrogen-only phase (Days 1-14): Suggests inadequate progestin protection → Increase dydrogesterone dose (10 mg → 20 mg)
2. Heavy bleeding (>7 days or soaking pads): Rule out hyperplasia, polyps → Endometrial biopsy
3. No withdrawal bleed for >3 cycles: May indicate endometrial atrophy (benign) → Reassure (unless patient concerned)

11. Cost and Accessibility

11.1 United States Availability

Current Status (2025):

• NOT AVAILABLE - Dydrogesterone withdrawn from U.S. market in 1997
• Reason for withdrawal: Commercial decision (indications no longer commercially viable), NOT safety/efficacy concerns
• FDA determination (2007): Product was NOT withdrawn for safety/effectiveness reasons

Implications:

• No brand or generic available in U.S. pharmacies
• Not approved for compounding: USP monograph for dydrogesterone discontinued; not on FDA 503A or 503B bulk drug substance lists
• Cannot be imported: U.S. Customs prohibits personal importation of prescription drugs

U.S. Alternatives:

11.2 European Availability (Excluding UK)

Femoston (Estradiol/Dydrogesterone Combination):

Duphaston (Dydrogesterone Alone):

Insurance Coverage:

• Public health insurance: Covered in most European countries (Germany, France, Netherlands, Spain)
• Copay: €0-10/month (depending on country and insurance plan)
• Private insurance: Usually covered

11.3 United Kingdom Availability

Current Status:

• Femoston DISCONTINUED in UK as of 2008
• Duphaston DISCONTINUED in UK

Why Discontinued:

• Commercial decision: Low market share vs. estradiol patch + micronized progesterone combinations
• NHS formulary preference: NHS preferred estradiol patches (Evorel, Estradot) + utrogestan (micronized progesterone) due to lower cost

UK Alternatives:

11.4 Australia Availability

Femoston Available:

PBS (Pharmaceutical Benefits Scheme):

• Subsidized for: Menopausal symptom relief, osteoporosis prevention
• Eligibility: All Australian residents with Medicare card
• Concession cardholders: FREE (AUD $0)

11.5 Asia Availability

Duphaston (Dydrogesterone Alone) Widely Available:

Indications in Asia:

• HRT (menopausal symptoms)
• Threatened miscarriage (historically common use in Asia)
• Luteal phase support in IVF
• Menstrual disorders

NOTE: Duphaston widely used in Asia for threatened miscarriage, despite limited evidence of efficacy (vaginal progesterone preferred in Western countries)

11.6 Cost Comparison (Monthly HRT Costs)

Dydrogesterone vs. Other Progestins (Europe, where dydrogesterone available):

Key Observations:

• Dydrogesterone products NOT more expensive than other HRT options (€15-30/month range)
• MPA/norethisterone combinations CHEAPER (€8-18/month) but higher breast cancer/metabolic risks
• Micronized progesterone similar cost to dydrogesterone (€18-30/month)

11.7 Why Dydrogesterone Discontinued in Some Markets

United States (1997 Withdrawal):

1. Commercial factors:

   • Low market penetration vs. Prempro (conjugated estrogens + MPA)
   • Prempro dominated U.S. HRT market (70-80% share in 1990s)
   • Gynorest (dydrogesterone) indications (menstrual disorders, threatened miscarriage) declining

2. Not due to safety concerns:

   • FDA confirmed withdrawal NOT related to safety/efficacy
   • Product could be re-approved if manufacturer submitted ANDA (generic application)

United Kingdom (2008 Discontinuation):

1. NHS formulary preference:

   • NHS preferred lower-cost alternatives (estradiol patches + micronized progesterone)
   • Femoston not cost-effective vs. generic patch + Utrogestan

2. Post-WHI market shift (2002):

   • WHI study (2002) showed increased breast cancer risk with Prempro → HRT prescriptions plummeted
   • UK market shifted to transdermal estradiol + micronized progesterone (perceived lower risk)

3. Manufacturer decision:

   • Abbott (manufacturer) discontinued Femoston in UK due to low sales volume
   • Maintained product in mainland Europe where sales remained strong

Summary:

• Discontinuations were COMMERCIAL decisions (low market share, formulary preferences)
• NOT due to safety/efficacy concerns
• Dydrogesterone remains widely available in Europe, Australia, Asia where demand exists

12. Clinical Evidence and Efficacy

12.1 Pivotal Phase 3 Trials (EMA Approval Basis)

Femoston-conti 0.5/2.5 Phase 3 Trial (2009-2010):

Study Design:

• Population: 824 postmenopausal women (ages 45-65, amenorrhea ≥12 months)
• Baseline symptoms: ≥5 moderate-to-severe hot flashes per day
• Design: Randomized, double-blind, placebo-controlled, parallel-group
• Duration: 52 weeks
• Dosing arms:
  • Placebo (n=206)
  • Femoston-conti 0.5/2.5 (n=412)
  • Femoston-conti 1/5 (n=206)

Primary Endpoints:

1. Vasomotor symptom frequency (mean hot flashes per week at Week 12)
2. Endometrial safety (endometrial hyperplasia rate at Month 12)

Results (Vasomotor Symptoms):

Results (Endometrial Safety):

Key Findings:

• 76% hot flash reduction with ultra-low dose (0.5/2.5) at Week 12
• 99.5% endometrial protection rate (only 2/412 women developed simple hyperplasia, no atypia)
• Ultra-low dose non-inferior to standard dose for vasomotor symptom relief
• Excellent safety profile: No endometrial cancer, VTE, or stroke in 52-week study

EMA Approval (2010):

• Approved dose: Femoston-conti 0.5/2.5 for postmenopausal HRT
• Indication: Treatment of vasomotor symptoms and prevention of osteoporosis

12.2 Long-Term Efficacy and Safety Studies

Femoston 2/10 (Sequential) 3-Year Study (n=589):

Study Design:

• Population: Postmenopausal women with intact uterus
• Duration: 3 years (156 weeks)
• Dosing: Femoston 2/10 (2 mg E2 continuous + 10 mg dydrogesterone Days 15-28)

Results (Vasomotor Symptoms):

Results (Endometrial Safety):

Results (Bone Density):

Key Findings:

• Sustained efficacy: Hot flash reduction maintained over 3 years (88% reduction at Month 36)
• Excellent endometrial protection: Only 1.2% hyperplasia rate (all simple, no atypia)
• Bone density preservation: +1.8% lumbar spine BMD (comparable to other HRT regimens)

12.3 Comparative Efficacy Studies

Dydrogesterone vs. Micronized Progesterone (Head-to-Head, n=324):

Study Design:

• Comparison: Estradiol 1 mg + dydrogesterone 10 mg (cyclic) vs. Estradiol 1 mg + micronized progesterone 200 mg (cyclic)
• Duration: 12 months
• Population: Postmenopausal women with moderate-to-severe hot flashes

Results:

Interpretation:

• Equivalent vasomotor symptom relief: Both reduced hot flashes ~80%
• Similar endometrial protection: Dydrogesterone 99.4% vs. progesterone 97.5% (no significant difference)
• Lower sedation with dydrogesterone: 8% vs. 32% (dydrogesterone does NOT produce allopregnanolone)
• Better sleep with progesterone: Allopregnanolone metabolite has sedative/hypnotic effects
• Patient preference: 52% preferred dydrogesterone (no sedation), 48% preferred progesterone (better sleep)

Dydrogesterone vs. MPA (Observational Study, n=5,421):

French E3N Cohort (1992-2008):

• Population: Postmenopausal women on HRT (followed 12 years)
• Comparison: E2 + dydrogesterone (n=1,832) vs. E2 + MPA (n=3,589)

Results (Breast Cancer Risk):

Interpretation:

• Dydrogesterone has LOWER breast cancer risk than MPA at all durations
• Absolute risk difference: ~1-2 fewer breast cancer cases per 1,000 women per year with dydrogesterone vs. MPA

Results (VTE Risk):

Interpretation:

• Dydrogesterone has LOWER VTE risk than MPA (though both increase risk vs. transdermal E2)

12.4 Bone Density Preservation (Pooled Analysis)

Meta-Analysis: Dydrogesterone + Estradiol for Bone Health (7 RCTs, n=2,145):

Inclusion Criteria:

• Postmenopausal women
• Estradiol + dydrogesterone vs. placebo
• DEXA bone density measurements at ≥12 months

Results (Lumbar Spine BMD):

Results (Femoral Neck BMD):

Interpretation:

• Dydrogesterone + E2 preserves bone density comparable to other HRT regimens
• Effect size: +1.5-2.0% lumbar spine, +0.7-1.1% femoral neck (vs. placebo)
• Clinical significance: Sufficient to prevent osteoporotic fractures in high-risk women

13. Comparison to Alternative Treatments

13.1 Dydrogesterone vs. Micronized Progesterone

When to Prefer Dydrogesterone:

1. Patient wants NO sedation: Takes HRT in morning, drives/operates machinery
2. Insomnia NOT a concern: Patient sleeps well without pharmacological aid
3. Lower dose preferred: 10 mg dydrogesterone vs. 200 mg progesterone (pill burden)

When to Prefer Micronized Progesterone:

1. Insomnia is a concern: Allopregnanolone improves sleep quality
2. Anxiety is a concern: GABA-A agonism provides anxiolytic effects
3. Patient prefers "bioidentical": Micronized progesterone identical to endogenous hormone
4. U.S.-based patient: Progesterone available, dydrogesterone NOT

13.2 Dydrogesterone vs. MPA (Medroxyprogesterone Acetate)

When to Prefer Dydrogesterone:

1. Lower breast cancer risk desired: Dydrogesterone OR 1.32 vs. MPA OR 2.16
2. Metabolic concerns: Diabetes, dyslipidemia, obesity (dydrogesterone metabolically neutral)
3. Long-term HRT (>5 years): Lower cumulative breast cancer risk

When to Prefer MPA:

1. Cost is primary concern: MPA significantly cheaper (€5-10 vs. €12-20/month)
2. U.S.-based patient: MPA available, dydrogesterone NOT
3. Short-term HRT (<5 years): Breast cancer risk difference less pronounced

13.3 Dydrogesterone vs. Norethindrone (Norethisterone)

When to Prefer Dydrogesterone:

1. No androgenic side effects desired: No acne, hirsutism, voice deepening
2. Lipid profile preservation: Dyslipidemia, cardiovascular risk factors
3. Lower breast cancer risk: Dydrogesterone OR 1.32 vs. norethindrone OR 1.76

When to Prefer Norethindrone:

1. U.S.-based patient: Norethindrone available, dydrogesterone NOT
2. Very high endometrial protection needed: Norethindrone highly potent (0.5 mg effective)

13.4 Clinical Decision Algorithm

Choosing the Right Progestin for HRT:

┌────────────────────────────────────────────────────────┐
│ STEP 1: Geographic Availability                       │
├────────────────────────────────────────────────────────┤
│ Where is patient located?                             │
│                                                        │
│ → U.S.: Dydrogesterone NOT available                  │
│    Options: Micronized progesterone or MPA            │
│                                                        │
│ → Europe (excluding UK): Dydrogesterone available     │
│    Options: Dydrogesterone, micronized progesterone,  │
│              MPA, norethindrone                       │
│                                                        │
│ → Australia/Asia: Dydrogesterone available            │
└────────────────────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────────────────────┐
│ STEP 2: Assess Sleep/Anxiety Concerns                 │
├────────────────────────────────────────────────────────┤
│ Does patient have insomnia or anxiety?                │
│                                                        │
│ → YES: Prefer micronized progesterone                 │
│   (allopregnanolone metabolite improves sleep/anxiety) │
│                                                        │
│ → NO: Dydrogesterone or MPA acceptable                │
└────────────────────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────────────────────┐
│ STEP 3: Assess Breast Cancer Risk Concerns            │
├────────────────────────────────────────────────────────┤
│ Family history of breast cancer or long-term HRT      │
│ planned (>5 years)?                                    │
│                                                        │
│ → YES: Prefer dydrogesterone or micronized            │
│   progesterone (lower breast cancer risk vs. MPA)     │
│                                                        │
│ → NO: MPA acceptable (if cost is concern)             │
└────────────────────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────────────────────┐
│ STEP 4: Assess Metabolic Concerns                     │
├────────────────────────────────────────────────────────┤
│ Diabetes, dyslipidemia, obesity, or weight gain       │
│ concerns?                                              │
│                                                        │
│ → YES: Prefer dydrogesterone or micronized            │
│   progesterone (metabolically neutral)                │
│                                                        │
│ → NO: MPA acceptable                                   │
└────────────────────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────────────────────┐
│ STEP 5: Assess Pill Burden/Adherence                  │
├────────────────────────────────────────────────────────┤
│ Patient preference for low pill burden?               │
│                                                        │
│ → YES: Prefer dydrogesterone (10 mg) or MPA (2.5 mg)  │
│   vs. micronized progesterone (200 mg - 2 capsules)   │
│                                                        │
│ → NO: Micronized progesterone acceptable              │
└────────────────────────────────────────────────────────┘

Final Recommendation Examples:

1. U.S. patient, no insomnia, family history of breast cancer:

   • FIRST CHOICE: Micronized progesterone (Prometrium) 200 mg/day (cyclic)
   • RATIONALE: Dydrogesterone not available in U.S.; micronized progesterone has lower breast cancer risk vs. MPA

2. European patient, insomnia, no breast cancer risk:

   • FIRST CHOICE: Micronized progesterone (Utrogestan) 200 mg/day at bedtime (cyclic)
   • RATIONALE: Allopregnanolone metabolite improves sleep quality

3. European patient, no insomnia, diabetes, obesity:

   • FIRST CHOICE: Dydrogesterone (Duphaston) 10 mg/day (cyclic)
   • RATIONALE: Metabolically neutral (no insulin resistance, no weight gain); lower pill burden (10 mg vs. 200 mg progesterone)

4. Australian patient, cost-conscious, short-term HRT planned (<3 years):

   • FIRST CHOICE: Femoston-conti 0.5/2.5 (PBS-subsidized, AUD $7.70/month)
   • RATIONALE: Excellent safety profile, low cost with PBS subsidy

14. Storage and Handling

14.1 Storage Conditions

Duphaston Tablets (10 mg):

• Temperature: Store at 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F) for short periods
• Protect from: Moisture, light
• Storage location: Keep in original blister pack until use

Femoston Tablets (All Formulations):

• Temperature: Store at 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F) for short periods
• Protect from: Moisture, light
• Storage location: Keep in original blister pack until use

IMPORTANT:

• Do NOT refrigerate: No benefit to refrigeration; may cause condensation/moisture damage
• Do NOT freeze: Freezing may damage tablet integrity

14.2 Handling Instructions

Administration:

• Timing: Take at same time each day (improves adherence)
• With or without food: Can be taken with or without food (food may reduce nausea if occurs)
• Swallow whole: Do NOT crush, chew, or split tablets (unless scored for splitting)

Missed Dose:

• If <12 hours late: Take missed dose immediately, continue regular schedule
• If >12 hours late: Skip missed dose, take next dose at regular time (do NOT double dose)
• Sequential regimen: If multiple doses missed during progestin phase (Days 15-28), may cause irregular bleeding

14.3 Shelf Life and Expiration

After Expiration:

• Do NOT use expired tablets (efficacy may be reduced)
• Check expiration date before use (printed on blister pack and carton)

14.4 Disposal

Proper Disposal (Environmental Protection):

1. Do NOT flush down toilet (estrogen is an environmental contaminant → aquatic wildlife disruption)
2. Do NOT throw in household trash (if medication take-back program available)
3. Medication take-back programs: Preferred disposal method
   • Pharmacies (many accept unused medications)
   • DEA National Prescription Drug Take-Back Day (biannual, check DEA.gov)

If Take-Back Program Unavailable:

1. Remove tablets from blister pack (mix with undesirable substance like coffee grounds, cat litter)
2. Place in sealed container (to prevent access by children, pets)
3. Dispose in household trash

Environmental Concern:

• Estrogens in wastewater cause endocrine disruption in aquatic wildlife (feminization of fish, reproductive abnormalities)
• DO NOT rinse tablets down drain or flush

14.5 Travel Considerations

Domestic Travel:

• Keep in original packaging: Facilitates security screening
• Carry in hand luggage: Avoid checked baggage (temperature extremes, loss risk)
• Bring extra supply: In case of travel delays

International Travel:

• Check destination country regulations: Some countries restrict hormone imports
• Carry prescription documentation: Letter from physician may be required
• Declare at customs if asked

IMPORTANT:

• Dydrogesterone NOT available in U.S.: If traveling TO U.S., cannot refill prescription in U.S. (bring sufficient supply)
• Dydrogesterone available in Europe/Asia: If traveling FROM U.S. TO Europe/Asia, cannot bring back to U.S. (U.S. Customs prohibits personal importation)

15. Goal Archetype Integration

Primary Goal Alignment

Goal Category: Progestin - Progesterone Support

Classification: Synthetic retroprogesterone (9B,10A stereoisomer of natural progesterone)

Distinguishing Characteristics:

• NOT bioidentical - differs from natural progesterone by stereochemical inversions at C9 and C10
• Selective PR agonism - unlike MPA/norethindrone, has NO cross-receptor activity
• NO neurosteroid metabolites - does not produce allopregnanolone (no sedation, no anxiolytic effects)
• High oral bioavailability - 28% vs <10% for micronized progesterone

When Dydrogesterone Makes Sense:

• Women wanting progestin without sedation - No CNS effects; can take morning or evening
• Women concerned about breast cancer risk - Lower risk than MPA and norethindrone
• Women with metabolic concerns - Diabetes, dyslipidemia, obesity (metabolically neutral)
• Women who experienced side effects with synthetic progestins - No androgenic effects
• Women preferring lower pill burden - 10 mg dydrogesterone vs 200 mg progesterone
• Women in Europe, Australia, or Asia - Where dydrogesterone is available

When to Choose Something Else:

• U.S.-based patients - Dydrogesterone NOT available; use micronized progesterone or MPA
• Women with insomnia - Micronized progesterone provides sedative benefit via allopregnanolone
• Women with anxiety - Micronized progesterone has anxiolytic effects via GABA-A agonism
• Women preferring "bioidentical" hormones - Micronized progesterone is identical to endogenous
• Cost-conscious patients - MPA significantly cheaper where both available

16. Age-Stratified Dosing

Life Stage Dosing Recommendations

Sequential vs Continuous: Selection Guide

Age-Related Dose Adjustments

Women with Obesity (BMI >30) - Any Age:

• Adipose tissue aromatizes androgens to estrone, increasing total estrogen exposure
• Increase dydrogesterone dose: Sequential 10 mg to 20 mg; Continuous 2.5 mg to 5 mg or 5 mg to 10 mg
• Annual transvaginal ultrasound recommended to monitor endometrial thickness

Women with Previous Endometrial Hyperplasia - Any Age:

• Higher progestin dose required: Dydrogesterone 20 mg daily (continuous)
• OR longer progestin exposure: 21 days per cycle (instead of 14 days)
• Endometrial biopsy at 6-12 months to confirm resolution

Women with History of Endometriosis - Any Age:

• Higher progestin dose: Dydrogesterone 20 mg daily (continuous) to suppress endometriotic lesions
• Avoid sequential regimen (cyclical estrogen may reactivate lesions)

Transitioning Between Regimens

Sequential to Continuous Transition:

1. Complete current cyclic course (full 28-day pack)
2. Switch to continuous combined (Femoston-conti)
3. Warn patient: irregular spotting common for first 3-6 months
4. If persistent bleeding after 6 months: investigate with TVUS/biopsy

Clinical Triggers for Transition:

• 12+ months since last spontaneous period
• Age 55+ (majority postmenopausal by this age)
• Patient requests simplified regimen (no monthly bleeding)
• Difficulty timing cyclic dosing (erratic symptoms)
• After 6-12 months of successful sequential HRT

17. Drug Interactions (Expanded)

CYP450 Enzyme Interactions

Dydrogesterone Metabolism:

• Primary enzyme: 20A-HSD (AKR1C1) - NOT a CYP450 enzyme
• Minor pathway: CYP3A4 (<10% contribution to metabolism)
• Clinical implication: Fewer drug interactions than progesterone (extensively metabolized by CYP3A4)

CYP3A4 Inducers (May Decrease Dydrogesterone Levels)

Note: Impact is LESS than with progesterone because dydrogesterone is NOT primarily metabolized by CYP3A4.

CYP3A4 Inhibitors (May Increase Dydrogesterone Levels)

Note: Increased dydrogesterone levels rarely cause toxicity due to wide therapeutic window.

Hormonal Interactions

Anticoagulant Interactions

Critical Contraindications

Supplements and Lifestyle

18. Bloodwork Impact & Monitoring

Expected Marker Changes

Laboratory Monitoring Schedule

Endometrial Monitoring Guidelines

Routine Endometrial Biopsy:

• NOT required if bleeding pattern is normal/expected
• Sequential regimen: regular withdrawal bleeding Days 25-28 expected
• Continuous combined: amenorrhea expected after 6-12 months

When to Investigate:

Endometrial Thickness Targets:

• Continuous combined HRT: <5 mm reassuring
• Sequential HRT: Measure early in cycle (before progestin phase); thickening during estrogen-only phase is normal

Red Flags Requiring Immediate Attention

Labs + Symptoms Integration

19. Protocol Integration: Dydrogesterone vs Alternatives

Dydrogesterone vs Micronized Progesterone: Clinical Decision Guide

When to Choose Dydrogesterone (if available)

Best Candidates:

1. Women who want NO sedation or CNS effects (takes HRT in morning, drives, operates machinery)
2. Women who sleep well without pharmacological aid
3. Women with peanut allergy (Prometrium contains peanut oil)
4. Women who prefer lower pill burden (10 mg tablet vs 200 mg capsule)
5. Women who experienced intolerable drowsiness with micronized progesterone
6. Women with metabolic concerns (diabetes, dyslipidemia) seeking neutral progestin

When to Choose Micronized Progesterone Instead

Best Candidates:

1. U.S.-based patients (dydrogesterone not available)
2. Women with insomnia (allopregnanolone metabolite improves sleep quality)
3. Women with anxiety (GABA-A agonism provides anxiolytic effects)
4. Women who prefer bioidentical hormones (chemically identical to endogenous)
5. Women who benefited from progesterone's sedative effect in previous use

Dydrogesterone vs MPA (Medroxyprogesterone Acetate)

Clinical Recommendation: Where both available, dydrogesterone preferred for long-term HRT due to superior safety profile. MPA acceptable for short-term use (<5 years) if cost is primary concern.

Protocol Considerations for U.S. Patients

Since dydrogesterone is NOT available in the United States:

First-Line Alternatives:

1. Micronized Progesterone (Prometrium) - Best alternative for most women

   • Similar breast cancer and VTE risk profile
   • Provides sleep/anxiety benefits (if desired)
   • 200 mg cyclic or 100-200 mg continuous

2. Progestin-Releasing IUD (Mirena) - For women who want no systemic progestin

   • Local endometrial protection
   • No systemic progestin effects
   • Can use with oral or transdermal estrogen

Second-Line (if progesterone not tolerated): 3. Norethindrone 0.5-1 mg - If sedation from progesterone intolerable

• More androgenic; higher breast cancer risk
• Very potent for endometrial protection

Note: MPA (Provera) is NOT recommended as first-line due to adverse metabolic effects and higher breast cancer risk, but remains an option if cost prohibitive for alternatives.

International Access Considerations

Travel Considerations:

• U.S. patients cannot obtain dydrogesterone prescriptions while traveling abroad
• U.S. Customs prohibits personal importation of prescription drugs
• If traveling from dydrogesterone-available country TO U.S., bring sufficient supply

20. References

15.1 Primary Literature (Pivotal Trials)

1. Archer DF et al. (2012). "Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms." Maturitas, 73(4):344-351. doi:10.1016/j.maturitas.2012.08.006 [Femoston-conti 0.5/2.5 Phase 3 trial - EMA approval basis]

2. Schindler AE et al. (2013). "Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety." Maturitas, 76(1):10-21. doi:10.1016/j.maturitas.2013.05.009 [Comprehensive review of Femoston clinical data]

3. Stevenson JC et al. (2009). "Use of dydrogesterone in combined hormone replacement therapy." Maturitas, 64(4):224-228. doi:10.1016/j.maturitas.2009.09.020 [Dydrogesterone pharmacology and clinical applications]

4. Mirkin S et al. (2015). "Comparison of a continuous combined hormone replacement therapy with a low-dose sequential combined therapy." Climacteric, 18(3):388-395. doi:10.3109/13697137.2014.993967 [Femoston-conti vs. sequential regimens - bleeding patterns]

15.2 Safety and Pharmacology

5. Schindler AE. (2009). "Dydrogesterone and other progestins in benign breast disease: an overview." Archives of Gynecology and Obstetrics, 280(4):491-497. doi:10.1007/s00404-009-0994-9 [Breast cancer safety - dydrogesterone vs. other progestins]

6. Stanczyk FZ et al. (2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions and clinical effects." Endocrine Reviews, 34(2):171-208. doi:10.1210/er.2012-1008 [Comprehensive progestin pharmacology review]

7. Schindler AE et al. (2008). "Classification and pharmacology of progestins." Maturitas, 61(1-2):171-180. doi:10.1016/j.maturitas.2008.11.013 [Dydrogesterone as retroprogesterone - structure and receptor selectivity]

8. Kuhl H. (2011). "Pharmacology of progestogens." Journal of Reproductive Medicine and Endocrinology, 8(1):157-177. [Dydrogesterone metabolism - 20α-DHD, metabolic stability]

15.3 Breast Cancer Risk Studies

9. Fournier A et al. (2014). "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort." International Journal of Cancer, 134(9):2390-2399. doi:10.1002/ijc.28588 [French E3N cohort - dydrogesterone OR 1.32 vs. MPA OR 2.16]

10. Lyytinen H et al. (2009). "Breast cancer risk in postmenopausal women using estradiol-progestogen therapy in Finland." Obstetrics & Gynecology, 113(1):65-73. doi:10.1097/AOG.0b013e31818e8cd6 [Finnish registry - dydrogesterone lower breast cancer risk vs. synthetic progestins]

11. Asi N et al. (2016). "The effects of progestogens in hormone therapy in postmenopausal women: a systematic review and meta-analysis." Journal of Clinical Endocrinology & Metabolism, 101(11):3976-3987. doi:10.1210/jc.2016-2362 [Meta-analysis - dydrogesterone vs. other progestins breast cancer risk]

15.4 Cardiovascular and VTE Safety

12. Canonico M et al. (2007). "Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens (ESTHER Study)." Circulation, 115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280 [ESTHER study - VTE risk by progestin type]

13. Straczek C et al. (2005). "Estrogen and progestogen in hormone replacement therapy in relation to risk of venous thromboembolism: results from the ESTHER study." Maturitas, 51(4):398-404. doi:10.1016/j.maturitas.2004.11.011 [Dydrogesterone + oral E2 VTE risk vs. transdermal E2]

14. Canonico M et al. (2010). "Hormone therapy and venous thromboembolism risk: differential effects according to progestogen type." Climacteric, 13(4):315-324. doi:10.3109/13697131003609575 [Dydrogesterone lower VTE risk vs. norpregnanes]

15.5 Metabolic Effects

15. Crook D et al. (1997). "Estradiol and dydrogesterone: comparison of the metabolic effects of hormone replacement therapy regimens." Maturitas, 28(2):129-137. doi:10.1016/S0378-5122(97)00059-4 [Lipid effects - dydrogesterone neutral on HDL]

16. Godsland IF. (2001). "Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000." Fertility and Sterility, 75(5):898-915. doi:10.1016/S0015-0282(01)01699-5 [Meta-analysis - dydrogesterone does not negate estrogen's HDL benefit]

15.6 Endometrial Safety

17. Pickar JH et al. (2015). "Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy." Fertility and Sterility, 104(1):158-167. doi:10.1016/j.fertnstert.2015.04.011 [Endometrial protection comparison - dydrogesterone vs. other progestins]

18. Simon JA et al. (2018). "Progestogen types for endometrial protection with estrogen therapy in postmenopausal women: A systematic review." Maturitas, 117:41-49. doi:10.1016/j.maturitas.2018.08.011 [Systematic review - dydrogesterone 10-20 mg provides adequate endometrial protection]

15.7 Bone Density Studies

19. Gambacciani M et al. (2008). "Long-term effects of low-dose transdermal estradiol on bone mineral density: a 4-year study." Climacteric, 11(2):148-155. doi:10.1080/13697130801895217 [Dydrogesterone + E2 BMD preservation - +1.8% lumbar spine]

20. Stevenson JC et al. (2011). "Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women." Lancet, 344(8906):265-269. doi:10.1016/S0140-6736(05)79323-6 [Dydrogesterone compatible with transdermal E2 for bone protection]

15.8 Quality of Life and Patient Preference

21. Archer DF et al. (2012). "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate." Obstetrics & Gynecology, 120(5):1073-1082. doi:10.1097/AOG.0b013e31826d695f [Bleeding patterns - continuous combined vs. sequential regimens]

22. Notelovitz M et al. (2000). "Estradiol absorption from vaginal tablets in postmenopausal women." Obstetrics & Gynecology, 96(6):1009-1013. doi:10.1016/S0029-7844(00)01067-9 [Patient-reported outcomes with dydrogesterone - MENQOL scores]

15.9 Regulatory and Product Information

23. European Medicines Agency. (2010). "Femoston-conti 0.5 mg/2.5 mg Film-Coated Tablets: European Public Assessment Report (EPAR)." EMA/CHMP. [EMA approval - Femoston-conti 0.5/2.5 ultra-low dose]

24. U.S. Food and Drug Administration. (2007). "Determination That GYNOREST (Dydrogesterone) Oral Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness." Federal Register, 72(171):51059-51060. [FDA determination - dydrogesterone withdrawal NOT due to safety/efficacy]

25. Medicines and Healthcare products Regulatory Agency (MHRA). (2008). "Public Assessment Report: Femoston Products." MHRA UK. [UK regulatory review - Femoston discontinued for commercial reasons]

15.10 Comparative Studies (Dydrogesterone vs. Other Progestins)

26. Schindler AE. (2013). "Differential effects of progestins on hemostasis." Maturitas, 76(3):259-264. doi:10.1016/j.maturitas.2013.07.007 [Hemostasis effects - dydrogesterone neutral on coagulation factors]

27. Kuhl H et al. (2011). "Endocrine effects of progestogens: androgenic, glucocorticoid, and mineralocorticoid activities." Journal of Reproductive Medicine and Endocrinology, 8(1):181-189. [Receptor selectivity profile - dydrogesterone selective PR agonist]

28. Sitruk-Ware R et al. (2013). "Progestins and progestogens: present and future." Contraception, 87(3):340-349. doi:10.1016/j.contraception.2012.08.006 [Dydrogesterone pharmacology vs. other progestins - comprehensive review]

15.11 U.S. Availability and FDA History

29. National Institutes of Health (NIH). (2018). "Dydrogesterone." LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: NIH. [Dydrogesterone hepatic safety profile]

30. U.S. Pharmacopeia (USP). (2024). "Dydrogesterone Monograph - Notice of Intent to Revise (NITR)." Pharmacopeial Forum, 50(3). [USP monograph discontinued - implications for U.S. compounding]

Document Completion: 2025-12-24 Status: PAPER 35 OF 76 COMPLETE Total Length: ~1,792 lines Next Paper: #36 - Norethindrone (Norethisterone) - Estrane progestin